<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04950075</url>
  </required_header>
  <id_info>
    <org_study_id>Ph2 INBRX-109 SA CS</org_study_id>
    <nct_id>NCT04950075</nct_id>
  </id_info>
  <brief_title>Study of INBRX-109 in Conventional Chondrosarcoma</brief_title>
  <official_title>A Randomized, Blinded, Placebo-controlled, Phase 2 Study of INBRX-109 in Unresectable or Metastatic Conventional Chondrosarcoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Inhibrx, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Inhibrx, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized, blinded, placebo-controlled, Phase 2 study of INBRX-109 in unresectable or&#xD;
      metastatic conventional chondrosarcoma patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, blinded, placebo-controlled, Phase 2 study of INBRX-109 in unresectable&#xD;
      or metastatic conventional chondrosarcoma patients. INBRX-109 is a recombinant humanized&#xD;
      tetravalent antibody targeting the human death receptor 5 (DR5).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 23, 2021</start_date>
  <completion_date type="Anticipated">June 2024</completion_date>
  <primary_completion_date type="Anticipated">February 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>INBRX-109 and placebo arms are in parallel. Patients on placebo are allowed to cross-over to open-label INBRX-109 at time of disease progression.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival per RECISTv1.1 comparing INBRX-109 and placebo</measure>
    <time_frame>3 years</time_frame>
    <description>Progression-free survival per RECISTv1.1 will be determined.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival of patients comparing INBRX-109 and placebo</measure>
    <time_frame>3 years</time_frame>
    <description>Overall survival will be determined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (in percent), duration of response (in time) and disease control rate (in percent)</measure>
    <time_frame>3 years</time_frame>
    <description>Tumor response will be determined by RECISTv1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life assessed by EORTC questionnaire for cancer patients (QLQ-C30) comparing INBRX-109 and placebo</measure>
    <time_frame>3 years</time_frame>
    <description>Quality of life will be determined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and grades of treatment-emergent adverse events including serious adverse events</measure>
    <time_frame>3 years</time_frame>
    <description>Adverse events will be assessed and severity assigned by using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of INBRX-109</measure>
    <time_frame>3 years</time_frame>
    <description>Frequency of anti-drug antibodies against INBRX-109 will be determined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the curve of INBRX-109</measure>
    <time_frame>3 years</time_frame>
    <description>The area under the curve of INBRX-109 will be determined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak serum concentration (Cmax) of INBRX-109</measure>
    <time_frame>3 years</time_frame>
    <description>The peak serum concentration (Cmax) of INBRX-109 will be determined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough serum concentration (Ctrough) of INBRX-109</measure>
    <time_frame>3 years</time_frame>
    <description>The trough serum concentration (Ctrough) of INBRX-109 will be determined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximum concentration (Tmax) of INBRX-109</measure>
    <time_frame>3 years</time_frame>
    <description>The time to maximum concentration (Tmax) of INBRX-109 will be determined.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">201</enrollment>
  <condition>Conventional Chondrosarcoma</condition>
  <arm_group>
    <arm_group_label>INBRX-109</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IV every three weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>IV every three weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>INBRX-109</intervention_name>
    <description>Tetravalent DR5 Agonist Antibody</description>
    <arm_group_label>INBRX-109</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Conventional chondrosarcoma, unresectable (=inoperable) or metastatic.&#xD;
&#xD;
          2. Measurable disease by RECISTv1.1. Note: Tumor lesions located in a previously&#xD;
             irradiated (or other locally treated) area will be considered measurable, provided&#xD;
             there has been clear imaging-based progression of the lesions since the time of&#xD;
             treatment.&#xD;
&#xD;
          3. Radiologic progression of disease per RECISTv1.1 criteria within 6 months prior to&#xD;
             screening for this study.&#xD;
&#xD;
          4. Adequate hematologic, coagulation, hepatic and renal function as defined per protocol.&#xD;
&#xD;
          5. Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1.&#xD;
&#xD;
          6. Estimated life expectancy of at least 12 weeks.&#xD;
&#xD;
          7. Availability of archival tissue or fresh cancer biopsy are mandatory.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any prior exposure to DR5 agonists.&#xD;
&#xD;
          2. Allergy or sensitivity to INBRX-109 or known allergies to CHO-produced antibodies.&#xD;
&#xD;
          3. Non-conventional chondrosarcoma, e.g., clear-cell, mesenchymal, extraskeletal myxoid,&#xD;
             myxoid, and dedifferentiated chondrosarcoma.&#xD;
&#xD;
          4. Prior or concurrent malignancies. Exception: Patients with a prior or concurrent&#xD;
             malignancy whose natural history or treatment does not have the potential to interfere&#xD;
             with the safety or efficacy assessments.&#xD;
&#xD;
          5. Chronic liver diseases. Exception: Patients with fatty liver disease are acceptable as&#xD;
             long as adequate hepatic function as defined in the inclusion criteria is confirmed.&#xD;
&#xD;
          6. Other exclusion criteria per protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Klaus Wagner, MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>Inhibrx, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michelle Darling</last_name>
    <phone>(919) 667-3242</phone>
    <email>michelle@inhibrx.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Miranda Fox</last_name>
    <email>miranda@inhibrx.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sarcoma Oncology Center</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90403</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Victoria Chua-Alcala</last_name>
      <phone>310-552-9999</phone>
      <email>vchua@sarcomaoncology.com</email>
    </contact>
    <investigator>
      <last_name>Sant P Chawla, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>June 14, 2021</study_first_submitted>
  <study_first_submitted_qc>June 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 6, 2021</study_first_posted>
  <last_update_submitted>October 20, 2021</last_update_submitted>
  <last_update_submitted_qc>October 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>DR5</keyword>
  <keyword>INBRX-109</keyword>
  <keyword>Apoptosis</keyword>
  <keyword>Programmed cell death</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chondrosarcoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

